1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Evolving Technology Platforms in Pharma-Biotech

Evolving Technology Platforms in Pharma-Biotech

  • November 2015
  • -
  • Frost & Sullivan
  • -
  • 87 pages

The road ahead toward precision medicine

The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines.

Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease.

This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or first-in-human studies. The RS also includes:

R&D portfolio and budgetary analysis
Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs
Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
Strategic evaluation of R&D portfolio

Research Scope

Research Focus

Report coverage and evaluation
The continued development of new treatments associated with the demographic trends and public health considerations is essential. The biopharmaceutical industry is one of the most research intensive sectors in developed nations. Investments are more than USD 125 billion, especially in early stages development phases, including the processes of discovering and developing new medicines. Biopharmaceutical innovation has played a major role in the improvement of both length and quality of life during the past decade, considerably reducing the disease burden for individuals and the society. Groundbreaking advances in the scientific understanding of the underlying mechanisms of disease are paving the way for precision medicine for the upcoming years. Indeed, the promise of personalized medicine is becoming a reality generating notable improvements in human health and the potential to reduce the socioeconomic burden of disease.

This research service (RS) depicts the current landscape of biopharmaceutical development, focusing on medicines that have progressed beyond early stage development and have recently entered clinical testing in human volunteers or firstin-human studies. The RS also includes:
- R&D portfolio and budgetary analysis
- Environmental analysis, depicting the key technical challenges, key business challenges, and emerging market needs
- Industry best practices and strategic insights, measuring performance, assessment of partnerships and alliances and R&D pipeline by milestones
- Strategic evaluation of R&D portfolio

Key Findings
The Biopharmaceutical Landscape
Current behavior of most top-tier biopharmaceutical companies
- The process of developing a new medicine is long and complex, and highly risky in nature due to the possibility of failures at each step in the process. As an overall estimation, an average cost to yield a single FDA-approved drug is approximately USD billion, and the entire research and development and FDA approval process time lasts between and years. Therefore, the need to reduce risk and guarantee efficient results is critical in our times.
- Factors affecting the cost, duration, and uncertainties associated with clinical trials, are continuously challenging the current drug development economic model and need to be noted and overcome. Interdisciplinary work, involving not only scientists from industry, government, and academia developing new tools and methods to improve R&D efficiency and designing new computer-based models and in silico approaches to predict how a candidate drug is absorbed, distributed, and eliminated from the body, but also, financial managers and economists who help to develop better predictive models, is gaining attention in this decade. The underlying goal is to improve the efficiency of the drug development process by narrowing the patient population where the drug has the best chance of success through precision medicine approaches, as well as, by eliminating candidate drugs before risky and costly clinical trials take place.
- Candidate drugs in clinical trials holding better chance of success, and involving a smaller number of clinical trials are expected to contribute to improve safety and efficacy. Accordingly, researchers are collaborating on pre-competitive research in areas such as biomarkers in order to accelerate research progress.
- Most top-tier biopharmaceutical companies have launched their open innovation programs to foster scientific innovation and collaborations worldwide. Broadly, though with some differences from one company to another, these programs consist of the development of opportunities with external collaborators through the free of charge access to the company’s tool compounds to conduct preclinical research in multiple therapeutic areas, evaluating multiple mechanisms of action (MoA). A Material Transfer Agreement is usually signed to protect the interests of both parties.
- Biomanufacturing in novel hubs such as Singapore’s Biopolis and Tuas Biomedical Parks constitutes one of the major trends for top-tier biopharmaceutical companies at present.

Table Of Contents

Evolving Technology Platforms in Pharma-Biotech
1. EXECUTIVE SUMMARY

Executive Summary
Research Scope
Research Methodology
Key Findings

2. DRUG DISCOVERY AND DEVELOPMENTA SNEAK PREVIEW

Drug Discovery and DevelopmentA Sneak Preview
Drug Discovery and Development Process
Development Cycle Times
Business Models and Participants
Business Model Evolution

3. STRATEGIC ASSESSMENT OF THE INDUSTRY ENVIRONMENT

Strategic Assessment of the Industry Environment
Drug Discovery and Development Focus
Global Expenditures
Manufacturing and Commercialization

4. BENCHMARKING MODEL AND ASSUMPTIONS

Benchmarking Model and Assumptions
RandD Benchmarking: Framework
RandD Benchmarking: Main Strengths by Company
RandD Benchmarking: Key Takeaways

5. CASE REPRESENTATIVE STUDIES:ABBVIE - AMGEN - BAYER - ROCHE

Case Representative Studies:AbbVie - Amgen - Bayer - Roche
Competitor Landscape
Core Therapeutic Areas
Principal Facts
Pharmacology Process
Pipeline
Intellectual Property
Income Statement: Explanatory Comments
Income Statement: Costs and Expenses
Research and Development
Emerging Markets
Partnerships and Acquisitions
Competitor Landscape
Core Therapeutic Areas
Principal Facts
Pipeline
Income Statement: Costs and Expenses
Research and Development
Discovery Research Model
Strategic Roadmap
Key Insights
Competitor Landscape
Core Therapeutic Areas
Principal Facts
Pipeline
Pharmacology Process
Income Statement: Costs and Expenses
Research and Development
Emerging Markets
Competitor Landscape
Core Therapeutic Areas
Principal Facts
Pipeline
Pharmacology Process
Income Statement: Costs and Expenses
Research and Development
Innovation Model
Emerging Markets
Partnerships
Legal Disclaimer

6. THE FROST and SULLIVAN STORY

The Frost and Sullivan Story
Value Proposition: Future of Your Company and Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Laboratory Products Purchasing Trends, 2016–2017

Global Laboratory Products Purchasing Trends, 2016–2017

  • $ 6000
  • Industry report
  • December 2016
  • by Frost & Sullivan

An End-user Perspective on the Purchasing Process, Product Budgets, and Top Companies for Laboratory Products Readers of Lab Manager Magazine were invited to participate in an online survey in July 2016. ...

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

PEGylated Proteins Market by Consumables, Services, Protein Type, Application, End-User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • November 2016
  • by MarketsandMarkets

The global PEGylated proteins market is expected to USD 1,137.8 million by 2021 from USD 690.6 million in 2016, at a CAGR of 10.5% between 2016 and 2021. The growth of this market is mainly driven by increase ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.